Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study

References

• Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640. doi:10.1136/bmjopen-2020-044640
   PubMed Web of Science ®Google Scholar
• Shiels MS, Almeida JS, García-Closas M, Albert PS, Freedman ND, Berrington de González A. Impact of population growth and aging on estimates of excess U.S. deaths during the COVID-19 pandemic, march to august 2020. Ann Intern Med. 2020;M20–7385.
   Web of Science ®Google Scholar
• Smorenberg A, Peters EJ, van Daele P, Nossent EJ, Muller M. How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. Eur J Intern Med. 2021;83:1–5. doi:10.1016/j.ejim.2020.11.02433303345
   PubMed Web of Science ®Google Scholar
• Yifan C, Jun P. Understanding the clinical features of Coronavirus disease 2019 from the perspective of aging: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:557333. doi:10.3389/fendo.2020.55733333262739
   PubMed Web of Science ®Google Scholar
• Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34(1):e00162–20. doi:10.1128/CMR.00162-2033055231
   PubMed Web of Science ®Google Scholar
• Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494):eaau9242. doi:10.1126/scitranslmed.aau924231142680
   PubMed Web of Science ®Google Scholar
• Hong YN, Xu J, Sasa GBK, Zhou KX, Ding XF. Remdesivir as a broad-spectrum antiviral drug against COVID-19. Eur Rev Med Pharmacol Sci. 2021;25(1):541–548. doi:10.26355/eurrev_202101_2442633506946
   PubMed Web of Science ®Google Scholar
• Perveen RA, Nasir M, Talha KA, Selina F, Islam MA. Systematic review on current antiviral therapy in COVID-19 pandemic. Med J Malaysia. 2020;75(6):710–716.33219182
   PubMedGoogle Scholar
• Shrestha DB, Budhathoki P, Syed NI, Rawal E, Raut S, Khadka S. Remdesivir: a potential game-changer or just a myth? A systematic review and meta-analysis. Life Sci. 2021;264:118663. doi:10.1016/j.lfs.2020.11866333121991
   PubMed Web of Science ®Google Scholar
• Kaka AS, MacDonald R, Greer N, et al. Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2021;M20–8148.
   Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020;32(3):107940. doi:10.1016/j.celrep.2020.10794032668216
   PubMed Web of Science ®Google Scholar
• Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2021;13(1):e13105. doi:10.15252/emmm.20201310533015938
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang LV. Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication. J Proteome Res. 2021;20(1):49–59. doi:10.1021/acs.jproteome.0c0052633347311
   PubMed Web of Science ®Google Scholar
• ACTT-1 Study Group Members; Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764.32445440
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10238):1694. doi:10.1016/S0140-6736(20)31022-9
   Web of Science ®Google Scholar
• Nasir M, Perveen RA, Murshed M, Nazneen R, Talha KA. Survival and biomarkers of COVID-19 patients treated with remdesivir and favipiravir in ICU during the peak of pandemic: a single center study in Bangladesh. J Pharm Res Int. 2021;32(45):14–22. doi:10.9734/jpri/2020/v32i4531088
   Web of Science ®Google Scholar
• Hoover RK, Alcorn H, Lawrence L, et al. Clinical pharmacokinetics of sulfobutylether-β-cyclodextrin in patients with varying degrees of renal impairment. J Clin Pharmacol. 2018;58(6):814–822. doi:10.1002/jcph.107729578585
   PubMed Web of Science ®Google Scholar
• Kiser TH, Fish DN, Aquilante CL, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19(1):32. doi:10.1186/s13054-015-0753-825645660
   PubMed Web of Science ®Google Scholar
• Pisa COVID-19 Study Group; Falcone M, Tiseo G, Barbieri G, et al. Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome Coronavirus 2 pneumonia: a prospective observational study. Open Forum Infect Dis. 2020;7(12):ofaa563. doi:10.1093/ofid/ofaa563.33365358
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary on compassionate use. Remdesivir. Gilead. European Medicines Agency, Amsterdam, The Netherlands; 2020. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf. Accessed 518, 2021.
   Google Scholar
• Yoshida Y, Gillet SA, Brown MI, et al. Clinical characteristics and outcomes in women and men hospitalized for coronavirus disease 2019 in New Orleans. Biol Sex Differ. 2021;12(1):20. doi:10.1186/s13293-021-00359-233546750
   PubMed Web of Science ®Google Scholar
• GS-US-540-5774 Investigators; Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi:10.1001/jama.2020.16349.32821939
   PubMed Web of Science ®Google Scholar
• GS-US-540-5773 Investigators; Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–1837. doi:10.1056/NEJMoa2015301.32459919
   PubMed Web of Science ®Google Scholar
• Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–2531. doi:10.1001/jama.2014.663424892770
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis Consortium; Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2013;381(9864):374. doi:10.1016/S0140-6736(13)60273-1.23374477
   PubMed Web of Science ®Google Scholar
• CKD Prognosis Consortium; Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. doi:10.1016/S2213-8587(15)00040-6.26028594
   PubMed Web of Science ®Google Scholar
• Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140–1145. doi:10.1016/j.ajic.2019.03.00331003750
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Donato FM, Messa P. Hepatitis C and its metabolic complications in kidney disease. Ann Hepatol. 2017;16(6):851–861. doi:10.5604/01.3001.0010.527529055921
   PubMed Web of Science ®Google Scholar
• Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020;31(8):1683–1687. doi:10.1681/ASN.202004043232371536
   PubMed Web of Science ®Google Scholar
• Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–227. doi:10.1016/j.kint.2020.04.00332327202
   PubMed Web of Science ®Google Scholar
• Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. 2020;144(5):213–221. doi:10.1159/00050730532203970
   PubMed Web of Science ®Google Scholar
• Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–1474. doi:10.5858/arpa.2020-0471-SA32818235
   PubMed Web of Science ®Google Scholar
• Fan F, Jia J, Li J, Huo Y, Zhang Y. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. BMC Nephrol. 2017;18(1):190. doi:10.1186/s12882-017-0608-428592280
   PubMed Web of Science ®Google Scholar
• Arnold LW, Hoy WE, Wang Z. The association between C-reactive protein levels and the risk for chronic kidney disease hospitalizations in adults of a remote Indigenous Australian community - a prospective cohort study. Nephrology (Carlton). 2017;22(9):699–705. doi:10.1111/nep.1284127312245
   PubMed Web of Science ®Google Scholar
• Gao J, Wang A, Li X, et al. The cumulative exposure to high-sensitivity C-reactive protein predicts the risk of chronic kidney diseases. Kidney Blood Press Res. 2020;45(1):84–94. doi:10.1159/00050425131794962
   PubMed Web of Science ®Google Scholar
• Mackanga JR, Alène C, Doumingou N, et al. The baseline glomerular filtration rate, predictive of six-year survival in sub-Saharan African patients on antiretroviral therapy for HIV: cohort study. Nephrol Ther. 2019;15(4):220–225. doi:10.1016/j.nephro.2019.02.00931088765
   PubMed Web of Science ®Google Scholar
• Liu YF, Zhang Z, Pan XL, et al. The chronic kidney disease and acute kidney injury involvement in COVID-19 pandemic: a systematic review and meta-analysis. PLoS One. 2021;16(1):e0244779. doi:10.1371/journal.pone.024477933400721
   PubMed Web of Science ®Google Scholar
• Rodríguez-Romo R, Benítez K, Barrera-Chimal J, et al. AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease. Kidney Int. 2016;89(2):363–373. doi:10.1038/ki.2015.32026509589
   PubMed Web of Science ®Google Scholar
• Sharma RK, Li J, Krishnan S, Richards EM, Raizada MK, Mohandas R. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. Clin Sci (Lond). 2021;135(1):1–17. doi:10.1042/CS2020048233399851
   PubMed Web of Science ®Google Scholar